Gregory M. Glenn, President, R&D at NOVAVAX INC (NVAX), sold 1,183 shares at $230.10 ($271K) on 2021-09-15, disclosed to the SEC on 2021-09-17.
Scheduled sale ($271k) by President, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $224.59 | 62 | $14K | 5.1% |
| 2 | $225.70 | 99 | $22K | 8.2% |
| 3 | $226.66 | 204 | $46K | 17.0% |
| 4 | $227.89 | 99 | $23K | 8.3% |
| 5 | $228.93 | 96 | $22K | 8.1% |
| 6 | $230.10 | 152 |
| $35K |
| 12.9% |
| 7 | $231.08 | 196 | $45K | 16.7% |
| 8 | $232.01 | 165 | $38K | 14.1% |
| 9 | $233.02 | 65 | $15K | 5.6% |
| 10 | $234.73 | 45 | $11K | 3.9% |
| Total | $229.34 avg | 1,183 | $271K | 100% |
| Filing → |
| NVAX | SELL | 2021-12-09 | $1.6M | — | Filing → |
| NVAX | SELL | 2021-12-02 | $3.2M | — | Filing → |
| NVAX | SELL | 2021-11-30 | $719K | — | Filing → |